- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Human epidermal growth factor receptor 2 (HER2)-low breast cancer
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 1.4MB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 769KB)
Trastuzumab Deruxtecan – November 2023
Trastuzumab Deruxtecan: Powder for I.V. infusion 100 mg; Enhertu®
Last updated
15 March 2024